FDA considers widening access to peptides promoted by wellness influencers | PBS News

The FDA advisory committee is considering lifting a ban on seven unapproved peptides that compounding pharmacies were blocked from producing in 2023, driven by surge in wellness influencer promotion and political support from HHS Secretary Robert F. Kennedy Jr. The decision hinges on whether to allow access to molecules with minimal clinical safety and efficacy data.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.